Stada Arz confirms takeover approaches

13 February 2017
mergers-acquisitions-big

Due to market rumors, German generic drugmaker Stada Arzneimittel (SAZ: Xetra) has confirmed that it has received two legally non-binding expressions of interest regarding a bid for the acquisition of up to 100% of the shares in the company,

One of these is from private equity firm Cinven Partners LLP at an indicative takeover price of 56.00 euros per Stada share. Other companies reportedly following the situation closely and could make a bid are Advent, Bain Capital, CVC and Permira, according to the Financial Times, which also said that the Cinven bid was worth around 3.6 billion euros (~$3.8 billion).

Stada’s shares were up 14.60% at 56.95 euros shortly after markets opened this morning.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics